| CAS |
No.69049-73-6 |
| 中文名称 |
多克罗 |
| 英文名称 |
Nedocromil |
| 分子式 |
C19H17NO7 |
| 分子量 |
371.34 |
| 溶解性 |
Soluble in DMSO ≥1mg/mL |
| 纯度 |
≥95% |
| 外观(性状) |
Light yellow to yellow Solid |
| 储存条件 |
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 靶点 |
Others |
| 通路 |
Immunology & Inflammation |
| 背景说明 |
据报道，Nedocromil 抑制多种介质的作用或形成，包括组胺，白三烯 C4 (LTC4) 和前列腺素 D2 (PGD2)。 |
| 生物活性 |
Nedocromil suppresses the action or formation of multiple mediators， including histamine， leukotriene C4 (LTC4)， and prostaglandin D2 (PGD2).[1-2] |
| In Vitro |
Nedocromil inhibits the release of histamine， LTC4， and PGD2 from mast cells challenged with antigen (with IC30 values of 2.1 μM， 2.3 μM， and 1.9 μM， respectively) and with anti-human IgE (IC30 values of 4.7 μM， 1.3 μM， and 1.3 μM， respectively)[1]. |
| In Vivo |
Nedocromil-treated diabetic mice show significantly improved heart function compared with controls. The contractility and relaxation forces show similar improvements. However， the cardiac function of Nedocromil-treated diabetic mice remains significantly impaired when compared with normal mice. Nedocromil can significantly improve cardiac function in mice with diabetic cardiomyopathy， but the treatment cannot restore normal function[2]. |
| 动物实验 |
Mice[2]8-12 weeks old C57/BL6 male mice between 23-25 g receive intraperitoneal (i.p.) injections of 50 mg/kg Streptozotocin (STZ)， dissolved in 100 mM citrate buffer pH 4.5， for five consecutive days. Diabetic mice (13-week-old) are randomly divided into three groups: 1) untreated group; 2) Nedocromil group， with Nedocromil released at the rate of 30 mg/kg per day from a subcutaneous (s.c.) pellet implantation; and vehicle group， with an inactive pellet implanted. Normal mice (non-diabetic) and normal mice that receive Nedocromil (30 mg/kg per day) are also included in this study for comparison. All sample groups included 15 mice (n=15)[2]. |
| 数据来源文献 |
[1]. Wells E， et al. Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine， LTC4， and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mastcells. J Immunol. 1986 Dec 15;137(12):3941-5.
[2]. Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation. Huang ZG， et al. PLoS One. 2013;8(3):e60827. |
| 规格 |
1mg 5mg 10mg 25mg 50mg |
| 单位 |
瓶 |
中文
英语
说明书下载
京公网安备 11011202000391号